{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:33:32Z","timestamp":1771554812843,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"a confidential project","award":["17CXZ010"],"award-info":[{"award-number":["17CXZ010"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aim<\/jats:title>\n                <jats:p>The use of cefoperazone\/sulbactam (CPZ\/SAM) could commonly cause vitamin K-dependent coagulation disorders and even hemorrhage sometimes. However, there is a lack of prediction tools estimating the risk for this. This study aimed at developing and internally validating a model for predicting CPZ\/SAM-associated coagulation disorders in Chinese inpatients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A case-control study was conducted in 11,092 adult inpatients admitted to a Chinese general hospital between 2020 and 2021 and treated with CPZ\/SAM. Patients with CPZ\/SAM-associated coagulation disorders were identified through the Adverse Drug Events Active Surveillance and Assessment System-II and subsequent manual evaluation. Controls were selected from eligible patients who didn\u2019t develop coagulation disorders after CPZ\/SAM therapy, with a 1:1 propensity score matching. The final predictors were obtained by univariable and multivariable logistic regression analyses. Internal validation and calibration for the model were performed using 1000 bootstrap resamplings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>258 patients were identified as CPZ\/SAM-associated coagulation disorders in 2184 patients eligible for inclusions and exclusions and the incidence was 11.8%. A final population of 252 cases and 252 controls was included for model development and validation. Malnutrition (OR\u2009=\u20092.41 (1.56\u20133.77)), history of recent bleeding (OR\u2009=\u20091.95 (1.32\u20132.90)), treatment duration (OR\u2009=\u20091.10 (1.07\u20131.14)), combination with carbapenems (OR\u2009=\u20094.43 (1.85\u201311.88)), and serum creatinine (OR\u2009=\u20091.01 (1.00\u20131.01)) were identified as final predictors. The model showed good discrimination, calibration, and clinical practicality, with the validated area under the receiver operating characteristic curve being 0.723 (0.683\u20130.770).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The model with good performance quantifies the risk for CPZ\/SAM-associated coagulation disorders, and may support individual assessment and interventions to mitigate the risk after external validation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-024-00761-7","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T11:02:41Z","timestamp":1720782161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development and internal validation of a model for predicting cefoperazone\/sulbactam-associated coagulation disorders in Chinese inpatients"],"prefix":"10.1186","volume":"25","author":[{"given":"An","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haili","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingchuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daihong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"761_CR1","doi-asserted-by":"crossref","unstructured":"Ji XW, Zhu X, Li Y, et al. Model-informed drug development of new cefoperazone sodium and sulbactam sodium combination (3:1): Pharmacokinetic\/Pharmacodynamic analysis and antibacterial efficacy against enterobacteriaceae [J]. Front Pharmacol. 2022;13:856792","DOI":"10.3389\/fphar.2022.856792"},{"key":"761_CR2","doi-asserted-by":"crossref","unstructured":"Chang P-C, Chen C-C, Lu YC, et al. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms [J]. J Microbiol Immunol Infect. 2018;51(2):207\u201313.","DOI":"10.1016\/j.jmii.2017.08.026"},{"key":"761_CR3","doi-asserted-by":"crossref","unstructured":"Hu HR. Fatal Vitamin K-dependent coagulopathy associated with cefoperazone\/sulbactam: a case report [J]. Drug Saf. 2019;6(1):6.","DOI":"10.1007\/s40800-019-0100-0"},{"key":"761_CR4","doi-asserted-by":"crossref","unstructured":"Cai Z, Yang W, He Y, et al. Cefoperazone\/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding: a case report and review of the literature [J]. Drug Saf 2016;3(1):2.","DOI":"10.1007\/s40800-016-0025-9"},{"issue":"10","key":"761_CR5","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1097\/CCM.0b013e3181eb9d2b","volume":"38","author":"TS Walsh","year":"2010","unstructured":"Walsh TS, Stanworth SJ, Prescott RJ, et al. Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units [J]. Crit Care Med. 2010;38(10):1939\u201346.","journal-title":"Crit Care Med"},{"issue":"12","key":"761_CR6","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/j.clinthera.2021.10.005","volume":"43","author":"S Wu","year":"2021","unstructured":"Wu S, Wu G, Wu H. A comparison of coagulation function in patients receiving aspirin and cefoperazone-sulbactam with and without Vitamin K(1): a retrospective, observational study [J]. Clin Ther. 2021;43(12):e335\u201345.","journal-title":"Clin Ther"},{"issue":"2","key":"761_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/(SICI)1099-1557(199903\/04)8:2<81::AID-PDS411>3.0.CO;2-G","volume":"8","author":"BL Strom","year":"1999","unstructured":"Strom BL, Schinnar R, Gibson GA, et al. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case [J]. Pharmacoepidemiol Drug Saf. 1999;8(2):81\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"761_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/BF01704604","volume":"20","author":"SD Rockoff","year":"1992","unstructured":"Rockoff SD, Blumenfrucht MJ, Irwin RJ Jr., et al. Vitamin K supplementation during prophylactic use of cefoperazone in urologic surgery [J]. Infection. 1992;20(3):146\u20138.","journal-title":"Infection"},{"issue":"7","key":"761_CR9","doi-asserted-by":"publisher","first-page":"e0158407","DOI":"10.1371\/journal.pone.0158407","volume":"11","author":"LJ Chen","year":"2016","unstructured":"Chen LJ, Hsiao FY, Shen LJ, et al. Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: a Nationwide Nested Case-Control Study [J]. PLoS ONE. 2016;11(7):e0158407.","journal-title":"PLoS ONE"},{"key":"761_CR10","doi-asserted-by":"crossref","unstructured":"Wang Q, Liang P, Xu Y, et al. Serum trough concentration threshold and risk factors of cefoperazone-induced coagulopathy in critically ill patients: a retrospective case-control study [J]. Eur J Clin Pharmacol. 2024.","DOI":"10.21203\/rs.3.rs-3085607\/v1"},{"key":"761_CR11","unstructured":"Zeng J, Zou M, Min M, et al. Characteristics and influencing factors of coagulation dysfunction caused by cefoperazone\/sulbactam [J]. Altern Ther Health Med. 2024."},{"key":"761_CR12","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.2147\/IDR.S429706","volume":"16","author":"W Miao","year":"2023","unstructured":"Miao W, Guo J, Cheng H, et al. Risk factors for cefoperazone\/sulbactam-induced coagulation disorder [J]. Infect Drug Resist. 2023;16:6277\u201384.","journal-title":"Infect drug Resist"},{"issue":"6","key":"761_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00228-023-03492-6","volume":"79","author":"H Guo","year":"2023","unstructured":"Guo H, Li P, Guo D, et al. Analysis of clinical characteristics and automatic monitoring of drug-induced arrhythmias in 167,546 inpatients [J]. Eur J Clin Pharmacol. 2023;79(6):759\u201365.","journal-title":"Eur J Clin Pharmacol"},{"key":"761_CR14","doi-asserted-by":"crossref","unstructured":"Yu C, Guo D, Yao C, et al. Development and validation of a nomogram for predicting drug-induced acute kidney injury in hospitalized patients: a case-control study based on propensity-score matching [J]. Front Pharmacol. 2021;12:657853.","DOI":"10.3389\/fphar.2021.657853"},{"issue":"2","key":"761_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions [J]. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"761_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis [J]. J Clin Epidemiol. 1996;49(12):1373\u20139.","journal-title":"J Clin Epidemiol"},{"key":"761_CR17","doi-asserted-by":"crossref","unstructured":"Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement [J]. BMJ (Clinical research ed). 2015;350g7594.","DOI":"10.1136\/bmj.g7594"},{"issue":"3","key":"761_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14740338.2020.1713090","volume":"19","author":"W Wang","year":"2020","unstructured":"Wang W, Liu Y, Yu C, et al. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study [J]. Exp Opin Drug Saf. 2020;19(3):339\u201347.","journal-title":"Exp Opin Drug Saf"},{"issue":"9","key":"761_CR19","doi-asserted-by":"publisher","first-page":"e0291658","DOI":"10.1371\/journal.pone.0291658","volume":"18","author":"H Bai","year":"2023","unstructured":"Bai H, Li H, Nie X, et al. Development and validation of a nomogram for predicting cefoperazone\/sulbactam-induced hypoprothrombinaemia in hospitalized adult patients [J]. PLoS ONE. 2023;18(9):e0291658.","journal-title":"PLoS ONE"},{"issue":"3","key":"761_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5005\/jp-journals-10071-24417","volume":"27","author":"KK Gudivada","year":"2023","unstructured":"Gudivada KK, Krishna B, Sampath S. Cefoperazone-induced Coagulopathy in critically ill patients admitted to Intensive Care Unit [J]. Indian J Crit care Med. 2023;27(3):183\u20139.","journal-title":"Indian J Crit care Medicine: peer-reviewed Official Publication Indian Soc Crit Care Med"},{"key":"761_CR21","doi-asserted-by":"crossref","unstructured":"Zhang L, Cai X, Peng F, et al. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone\/sulbactam therapy and other tigecycline-based combination therapies [J]. Front Pharmacol. 2023;14:1182644.","DOI":"10.3389\/fphar.2023.1182644"},{"issue":"1","key":"761_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","volume":"20","author":"M Guo","year":"2022","unstructured":"Guo M, Liang J, Li D, et al. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database [J]. Thromb J. 2022;20(1):12.","journal-title":"Thromb J"},{"issue":"1","key":"761_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ajcn\/87.1.106","volume":"87","author":"K Yamada","year":"2008","unstructured":"Yamada K, Furuya R, Takita T, et al. Simplified nutritional screening tools for patients on maintenance hemodialysis [J]. Am J Clin Nutr. 2008;87(1):106\u201313.","journal-title":"Am J Clin Nutr"},{"key":"761_CR24","doi-asserted-by":"crossref","unstructured":"Abd-El-Gawad WM, Abou-Hashem RM, El Maraghy MO, et al. The validity of Geriatric Nutrition Risk Index: simple tool for prediction of nutritional-related complication of hospitalized elderly patients. Comparison with Mini Nutritional Assessment [J]. Clin Nutr (Edinburgh, Scotland). 2014;33(6):1108\u201316.","DOI":"10.1016\/j.clnu.2013.12.005"},{"issue":"11","key":"761_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline [J]. Ann Intern Med. 2013;158(11):825\u201330.","journal-title":"Ann Intern Med"},{"issue":"5","key":"761_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0895-4356(03)00047-7","volume":"56","author":"EW Steyerberg","year":"2003","unstructured":"Steyerberg EW, Bleeker SE, Moll HA, et al. Internal and external validation of predictive models: a simulation study of bias and precision in small samples [J]. J Clin Epidemiol. 2003;56(5):441\u20137.","journal-title":"J Clin Epidemiol"},{"key":"761_CR27","doi-asserted-by":"crossref","unstructured":"Shao X, Ren Y, Xie N, et al. Effect of Cefoperazone\/Sulbactam on blood coagulation function in infected emergency department patients and the necessity of vitamin K1 (VK1) preventive intervention: a single-center, retrospective analysis [J]. Med Sci Monit. 2023;29:e939203.","DOI":"10.12659\/MSM.939203"},{"issue":"2","key":"761_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease [J]. N Engl J Med. 2011;365(2):147\u201356.","journal-title":"N Engl J Med"},{"issue":"9","key":"761_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJMra1208626","volume":"370","author":"BJ Hunt","year":"2014","unstructured":"Hunt BJ. Bleeding and coagulopathies in critical care [J]. N Engl J Med. 2014;370(9):847\u201359.","journal-title":"N Engl J Med"},{"key":"761_CR30","doi-asserted-by":"crossref","unstructured":"Levi M, Poll TVD. Coagulation in patients with severe sepsis [J]. Semin Thromb Hemost. 2015;41(1).","DOI":"10.1055\/s-0034-1398376"},{"issue":"5","key":"761_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MOH.0000000000000072","volume":"21","author":"A Falanga","year":"2014","unstructured":"Falanga A, Russo L, Milesi V. The coagulopathy of cancer [J]. Curr Opin Hematol. 2014;21(5):423\u20139.","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"761_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/j.1875-9114.1989.tb04122.x","volume":"9","author":"TH Grasela Jr","year":"1989","unstructured":"Grasela TH Jr., Walawander CA, Welage LS, et al. Prospective surveillance of antibiotic-associated coagulopathy in 970 patients [J]. Pharmacotherapy. 1989;9(3):158\u201364.","journal-title":"Pharmacotherapy"},{"issue":"5 Suppl","key":"761_CR33","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1053\/j.gastro.2009.08.046","volume":"137","author":"MJ Shearer","year":"2009","unstructured":"Shearer MJ. Vitamin K in parenteral nutrition [J]. Gastroenterology. 2009;137(5 Suppl):S105\u201318.","journal-title":"Gastroenterology"},{"key":"761_CR34","doi-asserted-by":"crossref","unstructured":"Moustafa F, Dopeux L, Mulliez A, et al. Severe undernutrition increases bleeding risk on vitamin-K antagonists [J]. Clin Nutr (Edinburgh, Scotland). 2021;40(4):2237\u201343.","DOI":"10.1016\/j.clnu.2020.10.002"},{"issue":"7","key":"761_CR35","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.clinthera.2009.07.015","volume":"31","author":"AH Abdelhafiz","year":"2009","unstructured":"Abdelhafiz AH, Myint MP, Tayek JA, et al. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis [J]. Clin Ther. 2009;31(7):1534\u20139.","journal-title":"Clin Ther"},{"issue":"4","key":"761_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/1120009X.2018.1452333","volume":"30","author":"HA Hakeam","year":"2018","unstructured":"Hakeam HA, Duhailib AL, Salahuddin Z. Impact of tigecycline versus imipenem-cilastatin on fibrinogen levels following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a randomized-controlled study [J]. J Chemother. 2018;30(4):224\u201332.","journal-title":"J Chemother"},{"issue":"2 Suppl","key":"761_CR37","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/CCM.0b013e3181c98d21","volume":"38","author":"M Levi","year":"2010","unstructured":"Levi M, Van Der Poll T. Inflammation and coagulation [J]. Crit Care Med. 2010;38(2 Suppl):S26\u201334.","journal-title":"Crit Care Med"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00761-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T11:05:34Z","timestamp":1720782334000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00761-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00761-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving humans was approved by the Ethics Committee of Chinese PLA General Hospital with a waiver of the requirement for informed consent (S2018-054-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}